B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment.
Saved in:
| Title: | B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment. |
|---|---|
| Authors: | Ott JM; Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Department of Internal Medicine I (Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics), University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, Tuebingen, Germany., Gassenmaier V; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, Tuebingen, Germany.; Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tuebingen, Tuebingen, Germany., Bitzer M; Department of Internal Medicine I (Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics), University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, Tuebingen, Germany.; Center for Personalized Medicine, Eberhard Karls University Tuebingen, Tuebingen, Germany., Schürch CM; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, Tuebingen, Germany.; Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tuebingen, Tuebingen, Germany., Heitmann JS; Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, Tuebingen, Germany., Hagelstein I; Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, Tuebingen, Germany.; German Cancer Consortium (DKTK), Partner Site Tuebingen, a Partnership Between DKFZ and University Hospital Tuebingen, Tuebingen, Germany. |
| Source: | Pathology oncology research : POR [Pathol Oncol Res] 2025 Aug 13; Vol. 31, pp. 1612186. Date of Electronic Publication: 2025 Aug 13 (Print Publication: 2025). |
| Publication Type: | Clinical Trial, Phase I; Journal Article |
| Journal Info: | Publisher: Frontiers Media S. A Country of Publication: Switzerland NLM ID: 9706087 Publication Model: eCollection Cited Medium: Internet ISSN: 1532-2807 (Electronic) Linking ISSN: 12194956 NLM ISO Abbreviation: Pathol Oncol Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
